Download full-text PDF |
Source |
---|
Antimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFHeliyon
January 2025
Institute of Nutrition and Food Science, University of Dhaka, Dhaka, Bangladesh.
The study aimed to analyze five commonly used veterinary antibiotics: tetracycline (TC), oxytetracycline (OTC), doxycycline (DOX), chlortetracycline (CTC), and enrofloxacin (ENR) in different types of milk samples, risk estimation, and to investigate the correlation between the presence of multiple antibiotic residues. About 27 milk samples, such as raw milk from collection centers, processed milk from processing plants, pasteurized, UHT, and flavored milk from retail stores, were examined using RP-HPLC against five veterinary antibiotics in Dhaka, Bangladesh. The correlation between antibiotics was analyzed using Pearson's correlation test.
View Article and Find Full Text PDFFront Antibiot
May 2024
Division of Emergency Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.
Background: The 2018 Infectious Disease Committee of the American Academy of Pediatrics stated that up to 3 weeks or less of doxycycline is safe in children of all ages. Our goal was to examine trends in doxycycline treatment for children with Lyme disease.
Methods: We assembled a prospective cohort of children aged 1 to 21 years with Lyme disease who presented to one of eight participating Pedi Lyme Net centers between 2015 and 2023.
J Antimicrob Chemother
January 2025
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Rev Med Suisse
January 2025
Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
This article focuses on two key innovations in dermatology: post-exposure prophylaxis for sexually transmitted infections (STIs) and new therapeutic options for inflammatory skin diseases. New European and American guidelines for doxycycline post-exposure prophylaxis (Doxy PEP) aim to prevent STIs in men who have sex with men (MSM) and individuals on HIV pre-exposure prophylaxis (PrEP). Doxy PEP is effective against syphilis and chlamydia, but its efficacy is limited by growing gonorrhea resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!